RUNX1 and acute myeloid leukemia: Similar to the response to induction chemotherapy, RUNX1-mutated newly diagnosed AML patients showed lower CR/CRi rates (50%) to venetoclax-based therapy than patients with wild-type RUNX1 (64%) [37].